Dr. Frank is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave # 300
Boston, MA 02215Phone+1 617-667-7000- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
David Geffen School of Medicine at UCLAClass of 2011
Certifications & Licensure
CA State Medical License 2013 - 2026
MA State Medical License Active through 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 279 citationsCAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed Hossain, Jean Oak
Nature Medicine. 2021-07-26 - 125 citationsIn Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, Leo I. Gordon, Jonathan W. Friedberg
Cancer Discovery. 2018-08-28 - 78 citationsMonitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-In...Matthew J. Frank, Nasheed Hossain, Ali Bukhari, Erin Dean, Jay Y. Spiegel
Journal of Clinical Oncology. 2021-06-16
Abstracts/Posters
- A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell LymphomaMatthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-CelMatthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and N...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
If CD19 CAR T Cell Therapy Fails in Lymphoma, Try a CD22 VersionJuly 11th, 2024
Hospital Affiliations
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
